Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Bendandi, M. (Maurizio) | |
dc.creator | Rodriguez-Calvillo, M. (Mercedes) | |
dc.creator | Inoges, S. (Susana) | |
dc.creator | Lopez-Diaz-de-Cerio, A. (Ascensión) | |
dc.creator | Perez-Simon, J.A. (José Antonio) | |
dc.creator | Rodriguez-Caballero, A. (Arancha) | |
dc.creator | Garcia-Montero, A. (A.) | |
dc.creator | Almeida, J. (J.) | |
dc.creator | Zabalegui, N. (Natalia) | |
dc.creator | Giraldo, P. (P.) | |
dc.creator | San-Miguel, J.F. (Jesús F.) | |
dc.creator | Orfao, A. (Alberto) | |
dc.date.accessioned | 2011-07-04T11:32:58Z | - |
dc.date.available | 2011-07-04T11:32:58Z | - |
dc.date.issued | 2006 | - |
dc.identifier.citation | Bendandi M, Rodriguez-Calvillo M, Inoges S, Lopez-Diaz de Cerio A, Perez-Simon JA, Rodriguez-Caballero A, et al. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk Lymphoma 2006 Jan;47(1):29-37. | es_ES |
dc.identifier.issn | 1029-2403 | - |
dc.identifier.uri | https://hdl.handle.net/10171/18722 | - |
dc.description.abstract | BACKGROUND AND OBJECTIVE: To combine the use of idiotype-pulsed allogeneic dendritic cells (alloDC) and soluble protein Id conjugated with KLH (Id-KLH) in a vaccine strategy for multiple myeloma (MM). DESIGN AND METHODS: Four MM patients received the combined vaccine after having experienced disease relapse/progression following reduced intensity conditioning (RIC) allogeneic stem cell transplantation (alloSCT) and failure to rescue therapy with donor lymphocyte infusion or chemotherapy (CHT). RESULTS: Vaccination was well tolerated and induced an anti-KLH antibody response in all 4 patients as well as substantial cell proliferation. In contrast, no case showed similar effects against either tumor-specific Id or irrelevant isotype control immunoglobulins (Ig). In turn, vaccination was associated with modulation of biological responses linked to both inflammatory and T-cell activation, with secretion of effector Th1 cytokines. In particular, an important increase in the spontaneous ex vivo secretion of TNFalpha, IL-6 and IFNgamma as well as IL-2 and IL-10 was frequently observed prior to the fourth vaccination. Moreover, in vitro stimulation with Id-KLH and Id-KLH plus alloDC, but not with alloDC alone was associated with an enhanced number of TNF-alpha+ T-cells and an increased secretion of IFNgamma and IL-2 before the third and fourth vaccination. From a clinical standpoint, 2 patients had a transient response and 1 has stable disease after stopping vaccination, while 3 of them ultimately progressed. INTERPRETATION AND CONCLUSIONS: The results show for the first time that the use of Id-pulsed alloDC following RIC alloSCT is safe and feasible. However, crucial strategy improvements are warranted to possibly achieve clinical benefit. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Informa Healthcare | es_ES |
dc.rights | info:eu-repo/semantics/closedAccess | - |
dc.subject | Cancer Vaccines/immunology | es_ES |
dc.subject | Vaccines, Conjugate/therapeutic use | es_ES |
dc.title | Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | http://informahealthcare.com/doi/abs/10.1080/10428190500272473 | es_ES |
Files in This Item:
There are no files associated with this item.
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.